论文部分内容阅读
目的探讨灯盏花素对慢性阻塞性肺疾病急性加重期(AECOPD)患者红细胞免疫水平的影响。方法将200例AECOPD患者随机分为观察组和对照组各100例。对照组给予常规治疗,观察组在对照组基础上加用灯盏花素治疗。对比2组临床疗效及治疗前后红细胞C3b受体花环(RBC-C3bRR)、红细胞免疫复合物花环(RBCICR)、红细胞免疫黏附促进因子(RFER)和红细胞免疫黏附抑制因子(RFIR)水平变化。结果观察组总有效率为95%高于对照组的90%(P<0.05)。治疗前2组红细胞免疫水平比较差异无统计学意义(P>0.05)。治疗后,2组RBC-ICR和RFIR水平均低于治疗前,RBC-C3bRR和RFER水平均高于治疗前,且观察组变化幅度大于对照组,差异均有统计学意义(P<0.05)。结论灯盏花素治疗AECOPD具有较好的临床疗效,提高了患者的红细胞免疫功能,值得临床推广应用。
Objective To investigate the effect of Breviscapine on erythrocyte immune function in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods 200 patients with AECOPD were randomly divided into observation group and control group of 100 cases. Control group given conventional treatment, the observation group in the control group plus Breviscapine treatment. The clinical efficacy and RBC-C3bRR, RBCICR, RFER and RFIR of erythrocyte C3bRR before and after treatment were compared between the two groups. Results The total effective rate in observation group was 95% higher than that in control group (P <0.05). There was no significant difference in erythrocyte immune level between the two groups before treatment (P> 0.05). After treatment, the levels of RBC-ICR and RFIR in two groups were lower than those before treatment, and the levels of RBC-C3bRR and RFER in the two groups were higher than those before treatment, and the changes in the observation group were greater than those in the control group (P <0.05). Conclusion Breviscapine treatment of AECOPD has a good clinical efficacy, improve the patient’s immune function of red blood cells, worthy of clinical application.